FGF/FGFR信号通路在肺鳞癌靶向治疗中的研究进展

肺癌是目前世界上发病率和死亡率最高的恶性肿瘤之一。肺鳞癌是仅次于肺腺癌的非小细胞肺癌（NSCLC）最常见的组织学类型，与肺腺癌相比，肺鳞癌的靶向治疗进展明显滞后。FGF/FGFR信号通路的异常改变与很多肿瘤有关，特别是肺鳞癌。FGFR基因扩增、体错义突变、染色体异位是诱导该通路改变的常见机制，故该通路可能是靶向治疗的新方向。本文将对在NSCLC中，特别是肺鳞癌，FGFR的改变以及相关的抑制剂作一综述。

Advances of FGF/FGFR Signaling Pathway in Targeted Therapy for Squamous Cell Lung Cancer

In current, lung cancer is one of the world’s malignant tumors with highest morbidity and mortality. Squamous cell lung cancer, ranks only second to adenocarcinoma, is the most common histological subtype in non-small cell lung cancer(NSCLC). Compared with lung adenocarcinoma, the progress of targeted treatment of squamous cell lung cancer has lagged behind. Aberrant signaling by fibroblast growth factors(FGFs) and fibroblast growth factor receptors(FGFRs) has been implicated in several human cancers, particularly in squamous cell lung cancer. FGFR gene amplifications, somatic missense mutations, chromosomal translocations are the most common mechanisms to induce aberrant activation of this pathway. Therefore, this pathway can be considered as a new approach for targeted therapy. This review summarizes the current knowledge about FGFR alterations in NSCLC and the relative inhibitors, particularly in squamous cell lung cancer.